Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease

  • Signal Transduct Target Ther. 2021 May 29;6(1):212. doi: 10.1038/s41392-021-00628-x.
Qi Sun   #  1 ,  Fei Ye   #  2 ,  Hao Liang   #  1 ,  Hongbo Liu   #  1 ,  Chunmei Li  3 ,  Roujian Lu  2 ,  Baoying Huang  2 ,  Li Zhao  2 ,  Wenjie Tan  4 ,  Luhua Lai  5  6
Affiliations
  • 1. BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
  • 2. NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China.
  • 3. Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • 4. NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China. [email protected].
  • 5. BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China. [email protected].
  • 6. Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. [email protected].
  • # Contributed equally.
PMID: 34052830 DOI: 10.1038/s41392-021-00628-x
Products